XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences Jan 04, 2021 4:05pm EST
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering Dec 21, 2020 5:00pm EST
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock Dec 10, 2020 6:22pm EST
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development Nov 16, 2020 7:30am EST
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results Nov 05, 2020 7:30am EST
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance Nov 03, 2020 7:30am EST
XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer Oct 28, 2020 7:30am EDT
